ALVO
$3.82
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Recent News
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect
This article first appeared on GuruFocus. Alvotech (NASDAQ:ALVO) is set to release its Q4 2025 earnings on March 18, 2026. The consensus estimate for Q4 2025 revenue is $0.16 billion, and the earnings are expected to come in at -$0.20 per share.
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump
If you are wondering whether Alvotech at around US$4.64 is a bargain or a value trap, you are not alone. This article is designed to help you frame that question clearly. The stock has been under pressure recently, with a 9.7% decline over the last 7 days, a 5.7% decline over 30 days, and longer term returns of a 7.2% decline year to date and a 64.3% decline over 1 year. These moves sit against a backdrop of ongoing interest in biosimilars and how companies like Alvotech position themselves...
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook
Alvotech (NasdaqGM:ALVO) reported positive clinical trial results for AVT80, its biosimilar candidate to Entyvio. The company also signed supply and commercialization agreements with Sandoz covering Canada, Australia, and New Zealand. These developments relate to a key biosimilar targeting a blockbuster inflammatory bowel disease treatment and expand Alvotech’s commercial reach. Alvotech focuses on developing and manufacturing biosimilars, an area that sits at the intersection of cost...
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80
Alvotech (NASDAQ:ALVO) is one of the Best Penny Stocks That Will Skyrocket. On February 5, Alvotech (NASDAQ:ALVO) announced strong initial results from a key clinical trial for AVT80. AVT80 is a potential biosimilar to the blockbuster drug, Entyvio, from Takeda. Management noted that the randomized, double-blind study successfully fit all primary goals, including proving AVT80 […]
Alvotech (ALVO): A Bull Case Theory
We came across a bullish thesis on Alvotech on r/valueinvesting by 123Thorr. In this article, we will summarize the bulls’ thesis on ALVO. Alvotech’s share was trading at $5.29 as of January 28th. ALVO’s trailing and forward P/E were 23.00 and 10.95, respectively according to Yahoo Finance. Alvotech ($ALVO) is emerging as a fast-growing biosimilars manufacturer, generating roughly $500 million in annual revenue […]